Page 3 - Clinical Development Updates News Today

30.03.2022 - Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for the treatment of patients with oHCM ...

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of... | March 24, 2022

Company reports revenues of EUR 13.4 million for the year ended December 31, 2021 As of December 31, 2021, cash and cash equivalents were EUR 32.3 million (USD 36.6 million) TWYMEEG

Perimeter Medical Imaging AI Reports 2020 Financial Results and Provides Corporate Update Perimeter Medical Imaging AI, Inc. a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today reported financial results for the year ended December 31, 2020 and provided a corporate update. Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “In 2020, we achieved a number of key milest...

Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 with product launch anticipated in 2021 1 Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type...